{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:33:00Z","timestamp":1786361580441,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Acute myeloid leukemia (AML) is a fast-progressing blood cancer marked by immature myeloid cells and poor survival rates. Most AML subtypes resist standard treatments, especially in older adults, highlighting the need for new targeted therapies. A hallmark of AML is LSD1 overexpression, which blocks blood cell maturation. Though some LSD1 inhibitors can trigger differentiation, their use is limited by toxicity and incomplete target inhibition.<\/jats:p>\n                  <jats:p>PROTAC degraders like MS9117 offer a promising solution by eliminating LSD1. This halts leukemia growth, promotes robust cell differentiation, and restores sensitivity to agents like all-trans retinoic acid, benefits not seen with traditional inhibitors. PROTACs can also target previously undruggable proteins, such as transcription factors, potentially enabling lower doses and fewer side effects. Several PROTAC therapies are now in AML trials. LSD1-targeted degradation is promising, but further research is needed to confirm its safety, overcome resistance, and identify optimal drug combinations for AML treatment.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004650","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:04:13Z","timestamp":1767960253000},"page":"2166-2167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic advances in acute myeloid leukemia: from LSD1 blockade to PROTAC-based strategies"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3980-2398","authenticated-orcid":false,"given":"Sarum A.","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Medicine, Wah Medical College, Wah Cantt, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9615-0915","authenticated-orcid":false,"given":"Muhammad A.","family":"Qamar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Spinghar Medical University, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad T.","family":"Feroze","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wah Medical College, Wah Cantt, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"R1-20260810","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","year":"2025","journal-title":"Prem J Sci"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark Res"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"53\u201361","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"R4-20260810","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1510319","article-title":"Discovery of highly potent and novel LSD1 inhibitors for the treatment of acute myeloid leukemia: structure-based virtual screening, molecular dynamics simulation, and biological evaluation","volume":"16","author":"Hong","year":"2025","journal-title":"Front Pharmacol"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fonc.2018.00255","article-title":"Lysine-specific demethylase 1A as a promising target in acute myeloid leukemia","volume":"8","author":"Magliulo","year":"2018","journal-title":"Front Oncol"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"1149754","DOI":"10.3389\/fonc.2023.1149754","article-title":"LSD1 inhibition modulates transcription factor networks in myeloid malignancies","volume":"13","author":"Hartung","year":"2023","journal-title":"Front Oncol"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"878\u201394","DOI":"10.1038\/s41388-021-02123-7","article-title":"Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML","volume":"41","author":"Nicosia","year":"2022","journal-title":"Oncogene"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"3185\u201395","DOI":"10.1002\/cncr.34366","article-title":"Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies","volume":"128","author":"Hollebecque","year":"2022","journal-title":"Cancer"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"e2425812122","DOI":"10.1073\/pnas.2425812122","article-title":"Discovery of an LSD1 PROTAC degrader","volume":"122","author":"Hosseini","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1002\/mco2.575","article-title":"PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives","volume":"5","author":"Vicente","year":"2024","journal-title":"MedComm (2020)"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:03:56Z","timestamp":1786359836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004650","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2025-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}